Related Experiment Video
Updated: May 1, 2026
In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
Published on: May 1, 2020
Effect of recombinant human epidermal growth factor on cutaneous scar quality in thyroidectomy patients
Jung U Shin1, Sang-Wook Kang, Jong Ju Jeong
1Department of Dermatology and Cutaneous Biology Research Institute and.
Background:
Epidermal growth factor (EGF) decreases inflammatory cell infiltration and TGF-β expression during wound healing. Several clinical studies show that recovery of various ulcer wounds, such as diabetic and radiation ulcer, is promoted by EGF.
Objective:
To evaluate effects of recombinant human epidermal growth factor (rhEGF) on cutaneous scar quality after thyroidectomy.
Method:
Scar quality was evaluated by Vancouver scar scale (VSS) in two groups of female thyroidectomy patients (control, n = 11; rhEGF-treated, n = 10). Scar erythema, pigmentation, elasticity and hydration were measured by mexameter, cutometer and corneometer.
Results:
Scar pliability (at 4 weeks) and thickness (2 weeks) after surgery were significantly lower in the rhEGF group than control. Total VSS score was significantly lower in the rhEGF group after 4 weeks. However, erythema, pigmentation, elasticity and hydration of the scar were not significantly different between groups.
Conclusion:
The early use of rhEGF in surgical wound healing may improve cutaneous scar quality.
Related Concept Videos
01:19Clinical Applications of Epidermal Stem Cells
01:24Healing II: Complications